calcium/calmodulin dependent protein kinase IDGenealiases: CKLiK · CaM-K1 · CaMKID
Q-omics provides the consensus-scored CAMK1D profile across patient tissues and cancer cell-line models. CAMK1D expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, CAMK1D is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CAMK1D protein abundance shows 20,352 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, KIRC, and GBM as cancer lineages where CAMK1D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAMK1D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAMK1D survival associations across molecular data types. CAMK1D RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAMK1D RNA expression–survival associations across cancer types. High CAMK1D expression shows unfavorable associations in UVM and UCEC, but favorable associations in LUAD, HNSC, KIRC and LGG. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for CAMK1D RNA expression.
This table summarizes CAMK1D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CAMK1D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAMK1D shows lower tumor expression in THCA, COAD and PAAD and higher tumor expression in KIRC, KICH and LIHC. The KIRC box plot shows higher CAMK1D RNA expression in tumor versus normal tissue (log2 FC = +1.325, t-test p < 0.001).
This table shows molecular features associated with CAMK1D in patient tissues and cancer cell lines. In patient samples, CAMK1D shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CAMK1D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
